VRCA

+ Watchlist + Portfolio

Verrica Pharmaceuticals Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.52
52-Week Range: $3.28 – $9.82
Market Cap: $75.24M
P/E (TTM): —
EPS (TTM): -1.75
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 17.45
PEG Ratio: —
Return on Equity: —
Return on Assets: -43.98%
Gross Margin: 37.68%
Operating Margin: -194.46%
Profit Margin: -102.84%
Current Ratio: 1.45
Debt/Equity: 0.42
Total Debt: $1.81M
Free Cash Flow: $-9.04M
Revenue Growth: -53.90%
Earnings Growth: —
Enterprise Value: $65.86M

VRCA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$9.03M	$5.12M	$7.57M	$35.58M
Cost of Revenue	$725.00K	$746.00K	$2.74M	$3.44M
Gross Profit	$8.31M	$4.38M	$4.83M	$32.14M
Research & Development	$12.20M	$20.30M	$11.84M	$8.86M
Selling, General & Admin	$17.41M	$47.30M	$58.82M	$35.22M
Operating Expenses	$29.60M	$67.60M	$70.66M	$44.08M
Operating Income	-$21.30M	-$63.22M	-$65.84M	-$11.94M
EBITDA	-$21.60M	-$62.20M	-$65.90M	-$9.36M
Pretax Income	-$24.49M	-$67.00M	-$76.58M	-$17.89M
Net Income	-$24.49M	-$67.00M	-$76.58M	-$17.89M
Diluted EPS	-7.20	-14.80	-14.80	-1.68
Diluted Shares	3.42M	4.53M	5.18M	10.65M

VRCA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.27M	$69.55M	$46.33M	$30.15M
Receivables	$487.00K	$4.42M	$77.00K	$5.40M
Inventory	$0.00	$1.02M	$2.46M	$2.24M
Current Assets	$39.12M	$77.53M	$51.18M	$42.54M
Total Assets	$44.72M	$81.60M	$54.13M	$47.13M
Current Liabilities	$3.46M	$17.02M	$29.01M	$16.44M
Long-Term Debt	—	$42.87M	$30.98M	—
Total Debt	$1.53M	$45.51M	$45.94M	$1.63M
Total Liabilities	$4.69M	$61.83M	$63.99M	$22.39M
Retained Earnings	-$163.45M	-$230.45M	-$307.03M	-$324.91M
Shareholders' Equity	$40.03M	$19.76M	-$9.86M	$24.74M
Working Capital	$35.66M	$60.51M	$22.17M	$26.10M

VRCA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.65M	-$38.58M	-$60.93M	-$17.63M
Capital Expenditure	-$302.00K	-$362.00K	-$27.00K	—
Free Cash Flow	-$18.95M	-$38.94M	-$60.95M	-$17.63M
Depreciation & Amortisation	$718.00K	$836.00K	$1.27M	$781.00K
Stock-Based Compensation	$4.99M	$14.38M	$7.16M	$3.32M
Investing Cash Flow	$54.04M	-$362.00K	-$19.00K	$0.00
Financing Cash Flow	-$16.87M	$74.21M	$37.73M	$1.45M
Net Change in Cash	$18.52M	$35.27M	-$23.22M	-$16.18M

VRCA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$3.44M	$12.70M	$14.34M	$5.09M	$5.02M	$5.86M
Cost of Revenue	$437.00K	$494.00K	$1.11M	$1.40M	$889.00K	$878.00K
Gross Profit	$3.00M	$12.21M	$13.23M	$3.69M	$4.13M	$4.98M
Research & Development	$2.28M	$1.85M	$2.21M	$2.52M	$3.86M	$6.03M
Selling, General & Admin	$8.85M	$8.85M	$9.40M	$8.12M	$9.99M	$10.35M
Operating Expenses	$11.13M	$10.70M	$11.61M	$10.64M	$13.85M	$16.38M
Operating Income	-$8.13M	$1.51M	$1.63M	-$6.95M	-$9.71M	-$11.40M
EBITDA	-$7.33M	$2.53M	$2.00M	-$6.57M	-$9.33M	-$12.78M
Pretax Income	-$9.74M	$204.00K	-$274.00K	-$8.07M	-$9.68M	-$13.15M
Net Income	-$9.74M	$204.00K	-$274.00K	-$8.07M	-$9.68M	-$13.15M
Diluted EPS	-1.00	0.02	-0.03	-0.57	-0.45	-0.62
Diluted Shares	9.48M	9.49M	9.49M	14.11M	21.31M	21.31M

VRCA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$29.59M	$15.40M	$21.10M	$30.15M	$20.60M	$11.20M
Receivables	$5.65M	$17.37M	$7.33M	$5.40M	$7.81M	$11.09M
Inventory	$2.46M	$2.52M	$2.30M	$2.24M	$1.97M	$2.71M
Current Assets	$39.47M	$36.78M	$36.27M	$42.54M	$34.13M	$32.64M
Total Assets	$42.18M	$39.11M	$40.90M	$47.13M	$38.79M	$36.02M
Current Liabilities	$29.40M	$29.22M	$28.91M	$16.44M	$16.22M	$22.44M
Long-Term Debt	$27.81M	$24.58M	$21.62M	—	—	—
Total Debt	$42.43M	$38.89M	$35.74M	$1.63M	$1.44M	$1.81M
Total Liabilities	$60.75M	$56.59M	$57.94M	$22.39M	$22.73M	$31.71M
Retained Earnings	-$316.77M	-$316.56M	-$316.84M	-$324.91M	-$334.60M	-$347.75M
Shareholders' Equity	-$18.58M	-$17.48M	-$17.04M	$24.74M	$16.05M	$4.31M
Working Capital	$10.08M	$7.56M	$7.37M	$26.10M	$17.91M	$10.20M
Net Debt	$11.04M	$21.86M	$12.98M	—	—	—

VRCA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$12.68M	-$10.04M	$9.69M	-$4.59M	-$9.16M	-$9.28M
Free Cash Flow	-$12.68M	-$10.04M	$9.69M	-$4.59M	-$9.16M	-$9.28M
Depreciation & Amortisation	$208.00K	$199.00K	$184.00K	$190.00K	$194.00K	$207.00K
Stock-Based Compensation	$1.03M	$888.00K	$718.00K	$686.00K	$897.00K	$1.21M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	-$4.06M	-$4.16M	-$3.98M	$13.64M	-$120.00K	-$126.00K
Net Change in Cash	-$16.73M	-$14.20M	$5.70M	$9.05M	-$9.28M	-$9.40M

Market Snapshot

About

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. The company focuses on developing and commercializing treatments for dermatological conditions with significant unmet medical needs. Verrica's lead product candidate targets common warts and molluscum contagiosum.